Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 95

1.

Structure-based redesign of an edema toxin inhibitor.

Chen D, Ma L, Kanalas JJ, Gao J, Pawlik J, Jimenez ME, Walter MA, Peterson JW, Gilbertson SR, Schein CH.

Bioorg Med Chem. 2012 Jan 1;20(1):368-76. doi: 10.1016/j.bmc.2011.10.091. Epub 2011 Nov 16.

2.

Pharmacophore selection and redesign of non-nucleotide inhibitors of anthrax edema factor.

Schein CH, Chen D, Ma L, Kanalas JJ, Gao J, Jimenez ME, Sower LE, Walter MA, Gilbertson SR, Peterson JW.

Toxins (Basel). 2012 Nov 8;4(11):1288-300. doi: 10.3390/toxins4111288. Review.

3.

Different Roles of N-Terminal and C-Terminal Domains in Calmodulin for Activation of Bacillus anthracis Edema Factor.

Lübker C, Dove S, Tang WJ, Urbauer RJ, Moskovitz J, Urbauer JL, Seifert R.

Toxins (Basel). 2015 Jul 13;7(7):2598-614. doi: 10.3390/toxins7072598.

4.

Bacillus anthracis edema factor substrate specificity: evidence for new modes of action.

Göttle M, Dove S, Seifert R.

Toxins (Basel). 2012 Jul;4(7):505-35. doi: 10.3390/toxins4070505. Epub 2012 Jul 6. Review.

5.

Structure-based inhibitor discovery against adenylyl cyclase toxins from pathogenic bacteria that cause anthrax and whooping cough.

Soelaiman S, Wei BQ, Bergson P, Lee YS, Shen Y, Mrksich M, Shoichet BK, Tang WJ.

J Biol Chem. 2003 Jul 11;278(28):25990-7. Epub 2003 Apr 3.

6.

The adenylyl cyclase activity of anthrax edema factor.

Tang WJ, Guo Q.

Mol Aspects Med. 2009 Dec;30(6):423-30. doi: 10.1016/j.mam.2009.06.001. Epub 2009 Jun 26. Review.

7.

Anthrax edema factor toxicity is strongly mediated by the N-end rule.

Leysath CE, Phillips DD, Crown D, Fattah RJ, Moayeri M, Leppla SH.

PLoS One. 2013 Aug 28;8(8):e74474. doi: 10.1371/journal.pone.0074474. eCollection 2013.

10.
11.

Testing the efficacy and toxicity of adenylyl cyclase inhibitors against enteric pathogens using in vitro and in vivo models of infection.

Moen ST, Blumentritt CA, Slater TM, Patel SD, Tutt CB, Estrella-Jimenez ME, Pawlik J, Sower L, Popov VL, Schein CH, Gilbertson SR, Peterson JW, Torres AG.

Infect Immun. 2010 Apr;78(4):1740-9. doi: 10.1128/IAI.01114-09. Epub 2010 Feb 1.

12.

Antiinflammatory cAMP signaling and cell migration genes co-opted by the anthrax bacillus.

Kim C, Wilcox-Adelman S, Sano Y, Tang WJ, Collier RJ, Park JM.

Proc Natl Acad Sci U S A. 2008 Apr 22;105(16):6150-5. doi: 10.1073/pnas.0800105105. Epub 2008 Apr 21.

13.

Effects of 39 Compounds on Calmodulin-Regulated Adenylyl Cyclases AC1 and Bacillus anthracis Edema Factor.

Lübker C, Seifert R.

PLoS One. 2015 May 6;10(5):e0124017. doi: 10.1371/journal.pone.0124017. eCollection 2015.

15.

Diminished but Not Abolished Effect of Two His351 Mutants of Anthrax Edema Factor in a Murine Model.

Zhao T, Zhao X, Liu J, Meng Y, Feng Y, Fang T, Zhang J, Yang X, Li J, Xu J, Chen W.

Toxins (Basel). 2016 Feb 2;8(2):35. doi: 10.3390/toxins8020035.

16.

Distinct interactions of 2'- and 3'-O-(N-methyl)anthraniloyl-isomers of ATP and GTP with the adenylyl cyclase toxin of Bacillus anthracis, edema factor.

Suryanarayana S, Wang JL, Richter M, Shen Y, Tang WJ, Lushington GH, Seifert R.

Biochem Pharmacol. 2009 Aug 1;78(3):224-30.

17.

Inhibition of the adenylyl cyclase toxin, edema factor, from Bacillus anthracis by a series of 18 mono- and bis-(M)ANT-substituted nucleoside 5'-triphosphates.

Taha H, Dove S, Geduhn J, König B, Shen Y, Tang WJ, Seifert R.

Naunyn Schmiedebergs Arch Pharmacol. 2012 Jan;385(1):57-68. doi: 10.1007/s00210-011-0688-9. Epub 2011 Sep 24.

PMID:
21947230
18.

Molecular analysis of the interaction of anthrax adenylyl cyclase toxin, edema factor, with 2'(3')-O-(N-(methyl)anthraniloyl)-substituted purine and pyrimidine nucleotides.

Taha HM, Schmidt J, Göttle M, Suryanarayana S, Shen Y, Tang WJ, Gille A, Geduhn J, König B, Dove S, Seifert R.

Mol Pharmacol. 2009 Mar;75(3):693-703. doi: 10.1124/mol.108.052340. Epub 2008 Dec 4.

19.

Contributions of edema factor and protective antigen to the induction of protective immunity by Bacillus anthracis edema toxin as an intranasal adjuvant.

Duverger A, Carré JM, Jee J, Leppla SH, Cormet-Boyaka E, Tang WJ, Tomé D, Boyaka PN.

J Immunol. 2010 Nov 15;185(10):5943-52. doi: 10.4049/jimmunol.0902795. Epub 2010 Oct 15.

20.

Selective inhibition of anthrax edema factor by adefovir, a drug for chronic hepatitis B virus infection.

Shen Y, Zhukovskaya NL, Zimmer MI, Soelaiman S, Bergson P, Wang CR, Gibbs CS, Tang WJ.

Proc Natl Acad Sci U S A. 2004 Mar 2;101(9):3242-7. Epub 2004 Feb 20.

Supplemental Content

Support Center